Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Formation of Scientific Advisory Board, Aastrom Biosciences (NASDAQ: ASTM)

ASTM announced the appointments of Daniel R. Salomon, M.D., Karen K. Hirschi, Ph.D., Marc Penn, M.D., Ph.D., FACC, and Mahendra Rao, M.D., Ph.D., to its newly formed scientific advisory board (NYSE:SAB). These distinguished scientists and clinicians will provide guidance in their respective areas of expertise in stem cell biology and cardiovascular disease.

Daniel R. Salomon, MD, chairman of Aastrom's SAB, is medical director of the Center for Organ and Cell Transplantation for Scripps Health at Scripps Green Hospital. He is an associate professor in the department of molecular and experimental medicine at The Scripps Research Institute. His research interests include investigation of how molecular mechanisms driving immune cell activation and tissue injury are regulated at the gene transcriptional and proteomic level. Dr. Salomon's work also focuses on mapping molecular networks that relate to clinical outcomes in cell and organ transplantation. He was the chair of the US FDA’s Biological Response Modifiers Advisory Committee and has served on multiple NIH study sections and special emphasis panels for over 15 years.

Karen K. Hirschi, PhD is deputy director of the Stem Cell and Regenerative Medicine Center and a professor in the departments of pediatrics and molecular and cellular biology in the Center for Gene Therapy at Baylor College of Medicine. She is also a professor in the department of bioengineering at Rice University. Dr. Hirschi is an expert in blood vessel formation and is currently studying the potential of adult and embryonic stem and progenitor cells to contribute to neovascularization in response to tissue injury and growth. She has published numerous articles about vascular development and gene therapy in leading medical publications.

Marc Penn, MD, PhD, FACC, is medical director of the Center for Cardiovascular Cell Therapy at the Cleveland Clinic. He is also a staff cardiologist in the department of cardiovascular medicine in the Heart & Vascular Institute of Cleveland Clinic. Dr. Penn has developed drug-delivery systems for the treatment of cardiovascular diseases and has produced studies to optimize gene therapy and stem cell therapy for the regeneration of myocardial tissue. Previously Dr. Penn has served as medical director of the coronary intensive care unit and director of the experimental cardiology laboratory at Cleveland Clinic.

Mahendra Rao, MD, PhD, is vice president of regenerative medicine, primary and stem cell systems, at Life Technologies. Dr. Rao is an expert in glial stem cell biology and for the last 20 years has acted as a scientific consultant for a broad range of constituencies in academia, government, regulatory affairs and industry. He has also served as chair of the FDA's Center for Biologics Evaluation and Research (CBER) Advisory committee as well as stem cell section chief in the laboratory of neuroscience at the National Institute of Aging. Dr. Rao maintains an academic appointment at the Buck Institute on Aging Research and has been a professor at the University Of Utah School Of Medicine, where his research focused on stem cells of the central nervous system.